Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899050 | 0.88 | ALDH1A1 (0.32) | ALDH1A1HTTTSHRHSD17B10MEN1 | |
| SCHEMBL4899046 | 0.88 | ALDH1A1 (0.32) | ALDH1A1HTTTSHRHSD17B10MEN1 | |
| SCHEMBL4895994 | 0.88 | ALDH1A1 (0.32) | ALDH1A1HTTTSHRHSD17B10MEN1 | |
| SCHEMBL4783105 | 0.88 | NOX1 (0.34) | ALDH1A1HTTTSHRHSD17B10TDP1 | |
| SCHEMBL4783109 | 0.88 | NOX1 (0.34) | ALDH1A1HTTTSHRHSD17B10TDP1 | |
| SCHEMBL4897704 | 0.87 | MAPT (0.35) | ALDH1A1HTTTSHRHSD17B10MEN1 | |
| SCHEMBL4891154 | 0.86 | ALDH1A1 (0.30) | ALDH1A1HTTMEN1KMT2ARAB9A | |
| SCHEMBL4899239 | 0.86 | ALDH1A1 (0.30) | ALDH1A1HTTMEN1KMT2ARAB9A | |
| SCHEMBL4899245 | 0.86 | ALDH1A1 (0.30) | ALDH1A1HTTMEN1KMT2ARAB9A | |
| SCHEMBL4897610 | 0.84 | NOX1 (0.32) | NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, MTOR | ALDH1A1 1752/4885HTT 3243/4885TSHR 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.